Breast Cancer
Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
Published in Women's Health Weekly, June 16th, 2011
2011 JUN 16 -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL--AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B." This follows the UK issuance which was granted in October of 2010 adding to the extensive patent estate.
The patent covers the novel polymorph form B of the oral histone deacetylase inhibitor, entinostat, being developed by Syndax for combination therapy with aromatase inhibitors for metastatic breast cancer and erlotinib for advanced non-small cell...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
BioSante Pharmaceuticals Completes Enrollment in LibiGel(R) Phase III Safety Study - Breast Cancer
Data on Breast Cancer Described by Researchers at National Cancer Institute - Breast Cancer
Data on Breast Cancer Discussed by Researchers at INSERM - Breast Cancer
Data on Breast Cancer Discussed by Researchers at University of Sao Paulo - Cesarean Section
Data on Cesarean Section Discussed by Researchers at University of Colorado - Cesarean Section
Data on Cesarean Section Published by Researchers at Wayne State University - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
